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Genome-wide Association of Copy-Number Variation
Reveals an Association between Short Stature
and the Presence of Low-Frequency Genomic Deletions
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Pamela J. Schreiner,15 James G. Wilson,16 Yiping Shen,5,6,7,19,* Bai-Lin Wu,6,7,17,18,19
and Joel N. Hirschhorn1,2,3,8,9,10,19,*
Height is a model polygenic trait that is highly heritable. Genome-wide association studies have identified hundreds of single-nucleotide
polymorphisms associated with stature, but the role of structural variation in determining height is largely unknown. We performed
a genome-wide association study of copy-number variation and stature in a clinical cohort of children who had undergone comparative
genomic hybridization (CGH) microarray analysis for clinical indications. We found that subjects with short stature had a greater global
burden of copy-number variants (CNVs) and a greater average CNV length than did controls (p< 0.002). These associations were present
for lower-frequency (<5%) and rare (<1%) deletions, but there were no significant associations seen for duplications. Known gene-dele-
tion syndromes did not account for our findings, and we saw no significant associations with tall stature.We then extended our findings
into a population-based cohort and found that, in agreement with the clinical cohort study, an increased burden of lower-frequency
deletions was associated with shorter stature (p ¼ 0.015). Our results suggest that in individuals undergoing copy-number analysis
for clinical indications, short stature increases the odds that a low-frequency deletionwill be found. Additionally, copy-number variation
might contribute to genetic variation in stature in the general population.Height is a highly heritable complex trait, and up to 90%
of the variation in height is due to genetic factors. It is
a classic polygenic trait and has been used as a model
for understanding the genetic architecture of complex
traits.1 Most association studies of polygenic traits—height
in particular—have examined common single-nucleotide
polymorphisms.2 A recent genome-wide association study
identified 180 independent loci associated with height,3
demonstrating the highly polygenic nature of stature.
Despite the tremendous progress made by these studies,
the loci identified only explain ~10% of the variation in
adult height.3 It is possible that other types of genetic
variation, such as low-frequency variation and/or copy-
number variation, might contribute to the genetic varia-
tion in stature.
Although there are a few examples of common copy-
number variants (CNVs) that are associated with complex
traits, such as obesity4 and Crohn disease,5 the data thus
far suggest that the majority of the heritability of complex
traits is not due to common copy-number variation.6 Most
studies showing association with copy-number variation1Division of Endocrinology, Children’s Hospital Boston, Boston, MA 02115,
bridge, MA 02141, USA; 3Metabolism Program, Broad Institute, Cambridge, MA
Medical Center, Harvard Medical School, in collaboration with Pfizer Inc. andM
Jiaotong University, Shanghai 200127, China; 6Department of Laboratory Med
02115, USA; 7Department of Pathology, Children’s Hospital Boston and Harvar
Hospital Boston, Boston, MA 02115, USA; 9Center for Basic and Translation
10Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; 11
University of Minnesota, Minneapolis, MN 55455, USA; 12Division of Sleep Me
sity of Virginia, Charlottesville, VA 22908, USA; 14Medical Genetics Institute
Epidemiology and Community Health, School of Public Health, University o
and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216
18Institutes of Biomedical Science, Fudan University, Shanghai 200032, China
19These authors contributed equally to this work
*Correspondence: yiping.shen@childrens.harvard.edu (Y.S.), joelh@broadinsti
DOI 10.1016/j.ajhg.2011.10.014. 2011 by The American Society of Human
The Americanin polygenic traits have found associations with low-
frequency CNVs that are not well tagged by SNPs.7 Studies
of schizophrenia8 and autism9 have identified an increased
global burden of rare CNVs in affected subjects. These
studies of rare copy-number variation have typically been
performed in cohorts ascertained for the presence of
disease. We sought to examine the role of both rare and
common CNVs in the stature of cohorts that were not
specifically ascertained on the basis of height.
To investigate whether CNVs play a role in short or
tall stature, we conducted a genome-wide association
study of copy-number burden in a cohort of children
who had undergone comparative genomic hybridization
(CGH) analysis for clinical indications, and we observed
an excess of rare deletions in children with short stature.
We then extended our findings to a large population-based
cohort and again observed an excess of low-frequency
deletions in shorter individuals. We also explored whether
individual regions in the genome have CNVs associated
with stature, and we preliminarily identified three candi-
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In the clinical cohort, subjects were eligible if they had a
height measurement recorded between the ages of 2 and
20 years and had had a chromosomal microarray per-
formed as part of their clinical evaluation. All microarrays
were performed on the Agilent 244K platform (Agilent
Technologies, Santa Clara, CA). Subjects with aneuploidy
and poor microarray quality were removed, leaving a
final sample size of 4,411 individuals. All CNV data were
called with NEXUS software (BioDiscovery, El Segundo,
California). Copy-number polymorphisms in candidate
regions were validated in a subgroup of individuals via
multiplex ligation-dependent probe amplification (Table
S1, available online).
The height measurements from the three visits closest
to the date of the microarray testing were abstracted from
the electronic medical record. Age- and height-adjusted
Z scores were calculated on the basis of the United States
CDC growth charts.10 The mean of the three height Z
scores was used as the final Z score. Tall and short cases
were defined as subjects with Z scores greater than þ2 and
less than 2 standard deviations, respectively. Individuals
with Z scores between 2 and þ2 were used as controls.
Ethnicity information was not available for subjects in
the clinical cohort and thus could not be controlled for
in the analysis.
All genome-wide association analyses of CNV burden
were performed with PLINK v1.07.11 We compared, in
both cases and controls, the distributions of the total
number of CNV segments, the total span of CNVs, and
the average CNV length. We then stratified the analysis
by deletions (copy number <2) and duplications (copy
number >2), as well as by CNV frequency. We defined
common CNVs as being present in greater than 5% of
our cohort and lower-frequency and rare CNVs as being
present in less than 5% and less than 1% of the cohort,
respectively. Statistical significance is based on one-tailed
comparisons of the observed metrics in cases versus in
controls (cases were tested for an excess of copy-number
variation) to the distribution of the same metrics in
10,000 permutations of case-control status. Using the
hg18 gene list of all Refseq genes provided on the PLINK
resources page, we were able to identify all CNVs that fell
within 20 kb of a gene. We then performed a genic CNV
analysis by including all such CNVs.
We performed a regional association analysis to look
for candidate genomic regions that contained CNVs
associated with height. All genomic coordinates provided
are in the NCBI36/hg18 genome build. Separate analyses
were performed for deletions and duplications. For this
analysis, the genome was divided into 10 kb segments.
For each segment with two or more CNVs, we first identi-
fied each individual with a CNV in that segment. Then, we
calculated the sum of all the individuals’ Z scores. For
example, if three individuals with deletions in a particular
10 kb segment had height Z scores of 2, 1, and þ1, the
sum of the Z scores for that segment would equal 2.
Consecutive segments with identical CNVs present in752 The American Journal of Human Genetics 89, 751–759, Decembthe same sets of individuals were collapsed into one larger
segment. We then performed 100,000 permutations in
which the Z scores of the 4,403 individual subjects with
CNVs were randomly shuffled. Using this permuted
data, we calculated summed Z scores for each segment.
We then counted the number of permuted summed Z
scores that were more extreme (i.e., more negative for a
negative sum or more positive for a positive sum) than
the observed summed Z score for each segment. For one-
tailed tests, we calculated a p value by dividing the
number of more extreme summed Z scores by 100,000.
Two-sided p values were calculated as twice the one-sided
p value (or 1 minus the one-sided p value—whichever was
greater). Regions were considered to have experiment-
wide significance if they had a p-value of %13105, i.e.,
if there were no permutations with a more extreme
summed Z score. This threshold is below a p value of
0.05 after a Bonferroni correction for the number of
segments with two or more CNVs (3,225 segments for
duplications and 2,720 segments for deletions). The geno-
mic inflation factor was calculated from the observed
p values as previously described.12,13 All statistical analyses
and permutations for the regional association analyses
were performed with custom Perl (v5.8) and R (v2.11)
scripts.
To extend the findings in the initial clinical cohort, we
used CNV data from the National Heart, Lung, and
Blood Institute (NHLBI)’s Candidate Gene Association
Resource (CARe), which is a consortium that performs
genetic analyses across nine NHLBI cohorts and encom-
passes cohorts with population-, community-, family-,
and hospital-based designs.14 A total of 7,363 African-
American individuals with height data available from
the Atherosclerosis Risk in Communities (ARIC), Coronary
Artery Risk Development in Young Adults (CARDIA),
Cleveland Family Study (CFS), Jackson Heart Study (JHS),
and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts
were genotyped on the Affymetrix 6.0 platform as part
of CARe.15 Individuals who were removed during the
genome-wide analysis of SNP association in this cohort15
were also excluded from this analysis. In total, 6,892
individuals were analyzed: 2,285 from ARIC, 668 from
CARDIA, 373 from CFS, 1,960 from JHS, and 1,606 from
MESA. To define adult height in the CARe cohorts, we
excluded men <23 years of age and women <21 years of
age, as well as individuals >85 years of age. Stratified by
cohort and gender, height was regressed on the basis of
age and study site, when available. Residuals were normal-
ized to a standard normal distribution. To account for the
family structure in CFS, we used the linear mixed effects
(LME) routine in genome-wide association analyses with
family data.16 Outliers (>4 SD or <4 SD) were excluded
from the analyses.
CNVs were called by two different methods—one de-
signed for known (more common) CNVs and one for
rarer CNVs. In brief, known CNVs (copy-number poly-
morphisms, or CNPs) were genotyped with Birdsuite17er 9, 2011
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Figure 1. Height Distribution of 4,411 Subjects in the Clinical
Cohortversion 1.6, which is based on two recently published
CNV maps.6,18 Rare CNVs were called with a hidden
Markov model implemented in Birdsuite, which, for each
sample, assigns a discrete copy number at each segment
of the genome, along with a LOD score that reflects the
confidence of the assignment. Individuals with a total
number of non-copy-number-2 CNV calls more than 3
standard deviations from the mean were removed. CNPs
with low call rate (<0.9), low frequency (<0.01), and bad
calls due to plate effects were removed. Rare CNV segments
with LOD scores <3 were removed. A repeat analysis
including only those CNVs with LOD scores >5 was per-
formed but did not substantially change the results. For
the analysis of common CNVs, only CNPs genotyped by
Canary with a frequency of >5% in the cohort were
included. For the analysis of lower-frequency and rare
CNVs, the common and rare CNVs were merged to create
a final dataset of CNV calls. CNV frequency was defined as
in the clinical cohort.
Stratified by deletions and duplications, the total
number of CNV segments, the total span of CNVs, and
the average CNV length for each individual were tabulated.
We then regressed the standardized height residuals
against each of these measures of CNV burden and cor-
rected for both genotyping-plate membership and the
top ten principal components. Analysis was indepen-
dently conducted for each CNV class (deletions and
duplications) and frequency threshold in each CARe
cohort, and data were then meta-analyzed for the final
evidence of association between global low-frequency
CNV burden and stature. CNV association analysis and
frequency calculation were done with PLINK v.1.07.11
Linear regression was performed with R v.2.8.1. Meta-
analysis was done with Metal (April 2010 release).19
This study complied with all necessary ethical proce-
dures concerning human subjects and was approved by
the Children’s Hospital Boston institutional review board.
Awaiver of consent was also granted for the chart review of
the clinical cohort. The component CARe studies were
approved by local institutional review boards, and the
analysis was approved by the Committee on the Use of
Humans as Experimental Subjects at the Massachusetts
Institute of Technology.The AmericanAfter compiling the CNV and height data in the clinical
cohort, we studied the 4,411 subjects who had height
data and for whom a clinician had obtained a microarray
to test for copy-number variation. Figure 1 shows the
height distribution of the 4,411 subjects, of whom 1,463
(33%) were female. The mean and median height Z scores
were 0.19 and 0.12, respectively, indicating that this
clinically ascertained population was slightly shorter
than the overall population. There were 415 short cases
with Z scores below 2, 196 tall cases with Z scores
above þ2, and 3,800 control subjects. We identified a to-
tal of 45,644 CNVs, including 23,931 deletions and
21,713 duplications, in 4,403 individuals. Eight subjects
did not have any CNVs identified. The respective median
values for deletion and duplication sizes were 115 kb and
143 kb. The respective interquartile ranges for deletion
and duplication sizes were 70–294 kb and 71–341 kb.
Histograms of deletion and duplication lengths are shown
in Figures S1 and S2. The mean number, total CNV length,
and average CNV length per individual were 10.3 kb, 2,944
kb, and 281 kb, respectively.
We first tested the general hypothesis that there was
a greater burden of copy-number variation in the cases
(tall and short) than in the normal-height controls from
the same cohort. The initial global burden analysis
comparing the CNV burden in all 611 cases (tall and short)
to that of the 3,800 controls showed a 1.17-fold increase in
total CNV length and a 1.15-fold increase in average CNV
size in cases (p ¼ 0.008 for total length and p ¼ 0.01 for
average size; Table 1). When we stratified the cases into
short cases and tall cases, the associations with copy-
number burden were present for short cases but not for
tall cases; the statistical significance increased after we
limited the cases to short individuals (Table 1). Thus, short
stature is associated with increased copy-number burden
in this cohort.
We next stratified the association analysis of the short
cases both by type of CNV (deletion or duplication) and
by CNV frequency (Table 2). Significant associations for
total CNV burden and average CNV size were found for
deletions but not for duplications. Furthermore, we
observed these associations only with lower-frequency
(frequency <5%) and rare (frequency <1%) deletions and
not with common (frequency >5%) deletions. Compared
to those in the controls, rare deletions in short cases showed
a 2.30-fold increase in total CNV length and a 1.98-fold
increase in average CNV size (p ¼ 0.005 and p ¼ 0.002,
respectively). Additionally, short cases showed higher rates
of CNVs in lower-frequency and rare deletions than did the
controls. Thus, the association between copy-number
burden and short stature is driven by lower-frequency and
rare deletions. These associations persisted when we
removed individualswith knowngene-deletionor -duplica-
tion syndromes associated with short stature (Table S2).We
attempted to further characterize this association on the
basis of CNV size but were not able to identify a specific
range of CNV sizes associated with short stature. However,Journal of Human Genetics 89, 751–759, December 9, 2011 753
Table 1. Association Analysis of CNV Burden
Control
Tall and
Short Cases p Value Short Cases p Value Tall Cases p Value
Global CNV Burden
Total Number of CNVs 39,241 6,403 4,307 2,096
Number of CNVs per individual 10.3 10.5 0.21 10.4 0.41 10.7 0.12
Total CNV burden per individual (kb) 2,879 3,381 0.008 3,697 0.001 2,711 0.7
Average CNV size per individual (kb) 276 317 0.01 348 0.002 253 0.85
Genic CNV Burden
Total Number of CNVs 28,785 4,710 3,178 1,532
Number of CNVs per individual 7.6 7.7 0.19 7.7 0.31 7.8 0.17
Total CNV burden per individual (kb) 2,259 2,752 0.009 3,090 0.001 2,036 0.82
Average CNV size per individual (kb) 298 348 0.01 390 0.002 257 0.96
p values showing significant associations are in bold. Tall and short cases were defined as subjects with Z scores greater than þ2 and less than 2 standard
deviations respectively. Individuals with Z scores between 2 and þ2 were used as controls. ‘‘Global CNV’’ refers to all CNVs in the genome. ‘‘Genic CNV’’ refers
to all CNVs within 20 kb of a known gene.short cases showed higher rates of lower-frequency dele-
tions with length <100 kb and >500 kb (p ¼ 0.01 and
p ¼ 0.004, respectively) than did the controls.
In addition to assessing total CNV burden, we repeated
our analyses by using only genic CNVs (deletions or dupli-
cations within 20 kb of known genes; Table 1 and Table
S3). Compared to the control subjects, all cases (short
and tall) had a 1.22-fold increase in genic CNV burden (p
¼ 0.009) and a 1.17-fold increase in average CNV length
(p ¼ 0.01). As with the overall burden analyses, an associ-
ation was present for short cases (1.37-fold increased
burden and 1.31-fold increased length, p ¼ 0.001 and
0.002, respectively) but not for tall cases. Within the short
cases, we observed the association with deletions (p ¼
0.003 and p ¼ 0.0002 for total burden and average length,
respectively) but not with duplications. Further stratifica-
tion by CNV frequency in this smaller set of CNVs did
not yield any convincingly significant results (Table S3).
Additionally, we performed linear-regression analyses of
CNV burden versus height as a quantitative trait rather
than as a case-control analysis. We observed all of the asso-
ciations seen in our case-control analyses. Specifically, the
analyses showed an inverse correlation between height
and both the total CNV burden (p ¼ 0.013) and average
CNV size (p ¼ 3.1 3 105) (Table S4 and Figure S3). These
findings were stronger for genic CNVs and were driven by
low-frequency and rare deletions (Table S5 and Figure S4).
To explore whether the effects of CNV burden in the quan-
titative-trait analysis differ between shorter and taller indi-
viduals, we divided the cohort into subgroups with height
Z scores greater than or less than zero, and the associations
were only present for those subjects with height Z scores
below zero (Table S4). This result is also consistent with
the case-control analysis. In this quantitative-trait analysis,
we saw an association between common deletion burden
and increased height, but this result was not seen in the754 The American Journal of Human Genetics 89, 751–759, Decembcase-control analysis and did not replicate in the popula-
tion-based cohort (see below).
Because our clinical cohort represents a highly ascer-
tained population that underwent CNV analysis as a result
of clinical concerns, the subjects are probably enriched for
rare CNVs. Thus, it is difficult to draw any more general
conclusions regarding the etiological role of CNVs in short
stature. We asked whether our findings that short individ-
uals show an increased burden of deletions would extend
into a population-based cohort. To this end, we used
CNV data from NHLBI’s CARe.14,15 In total, we analyzed
the CNV burden of 6,892 African-American individuals
from five population-based cohorts. We assessed the asso-
ciation—stratified by deletions and duplications—between
three CNV burden measures (total number of rare CNVs,
total CNV burden, and average CNV length) and height
as a quantitative phenotype. In this analysis, we adjusted
for covariates, including the top ten principal components
of ancestry on the basis of genome-wide SNP genotypes
from CARe (Table 3).
In general, we observed that shorter stature is associated
with a significantly increased total burden of lower-
frequency CNV deletions (p ¼ 0.015) (Table 3). Each of
the three measures of CNV burden (total burden, average
CNV size, and total number of CNV segments) was signif-
icantly associated with height when we confined our anal-
ysis to CNVs within 20 kb of genes (Table 3), suggesting
that deletions disrupting gene function might have a role
in shorter stature. In the CARe cohort this translates into
an average 0.3 cm decrement in height for every 1 Mb
increase in lower-frequency deletion burden and a decre-
ment of 0.4 cm for every 1 Mb increase in lower-frequency
genic deletion burden. We also examined associations
between total burdens of lower-frequency duplications
and stature and did not observe any significant trends,
although our power to detect associations is lower aser 9, 2011
Table 2. Association Analysis of CNV Burden in 415 Short Cases versus 3,800 Controls
All Frequencies Common (>5%) Lower Frequency (<5%) Rare (<1%)
Case Control p Value Case Control p Value Case Control p Value Case Control p Value
Deletions and Duplications
Total number of CNVs 4,307 39,241 2,985 27,498 1,373 12,236 819 6,985
Number of CNVs
per individual
10.4 10.3 0.41 7.2 7.2 0.6 3.3 3.2 0.25 2 1.8 0.12
Total CNV burden
per individual (kb)
3,697 2,879 0.001 1,725 1,768 0.77 2,107 1,226 0.0006 2,052 1,068 0.001
Average CNV size
per individual (kb)
348 276 0.002 233 237 0.74 534 359 0.003 774 449 0.0004
Deletions Only
Total number of CNVs 2,253 20,589 1,434 13,812 826 6,840 446 3,549
Number of CNVs
per individual
5.4 5.4 0.47 3.6 3.6 0.92 2 1.8 0.02 1.1 0.9 0.02
Total CNV burden
per individual (kb)
2,073 1,421 0.003 814 849 0.78 1,567 743 0.002 1,786 776 0.005
Average CNV size
per individual (kb)
415 250 0.0002 205 202 0.35 595 314 0.0005 888 449 0.002
Duplications Only
Total number of CNVs 2,054 18,652 1,269 11,368 809 7,462 494 4,504
Number of CNVs per
individual
4.9 4.9 0.39 3.1 3 0.26 1.9 2 0.51 1.2 1.2 0.4
Total CNV burden
per individual (kb)
1,673 1,503 0.08 865 866 0.5 1,086 867 0.05 993 743 0.07
Average CNV size
per individual (kb)
310 295 0.22 248 260 0.84 417 372 0.20 486 418 0.20
p values showing significant associations are in bold.a result of fewer duplications (Table 3). For common (>5%
frequency) CNVs, we did not see any associations with
height except for a weak association between the number
of common deletions and decreasing height (p ¼ 0.036).
This is the opposite of the effect seen for common dele-
tions in the clinical cohort. All of our findings were consis-
tent across the five cohorts within CARe and showed little
evidence of heterogeneity.
As an additional exploratory analysis, we examined
whether any regions of the genome showed associations
between height and copy-number variation of any kind.
We divided the genome into segments and tested each
segment for an association between height and either dele-
tions or duplications within that segment; significance was
assessed by permutation. Height proved to be associated
much more with deletions than with duplications:
Genomic inflation factors for deletions and duplications
were 1.75 and 1.17, respectively (Figure 2). Three prelimi-
nary candidate regions were identified as having signifi-
cant associations with stature after we corrected for
multiple testing (nominal p < 13105) in our cohort:
a duplication at 11q11 and deletions at 14q11.2 and
17q21.31 (Figures S5–S7, Table S6). Detection of these
CNVs was confirmed by multiplex ligation-dependentThe Americanprobe amplification (Figure S8). For each of these three
regions, deletions and duplications had opposite effects
on height. These regions all display common copy-number
variation,20 and 22%–49% of the individuals in our sample
had CNVs in each region. Therefore, these regions do not
account for our earlier observation of an excess of rare dele-
tions in individuals with short stature. In addition to these
three areas with common CNVs, we observed a 30 kb
region that was directly adjacent to the 11q11 polymor-
phism and that was associated with increased height
when deleted. However, this result is only based on the
observation of a regional deletion in two subjects with
extremely tall stature (Z scores of þ3.3 and þ4.3) and
thus requires additional replication if we are to be certain
of its validity.
Our study demonstrates an increased global burden of
CNVs in individuals with short stature. This increased
burden is driven by an excess of lower-frequency deletions.
Furthermore, deletions intersecting with known genes
were more common among cases of short stature than
among controls. Similar findings of increased genic CNV
burden have been found in prior studies of complex traits;
an increase in rare genic CNVs has been found with
autism,9 and rare large (>100 kb) CNVs have been foundJournal of Human Genetics 89, 751–759, December 9, 2011 755
Table 3. CNV Association Analysis in Population-Based Replication Cohort
Common (>5%) Lower Frequency (<5%) Rare (<1%)
B
Standard
Error p B
Standard
Error p B
Standard
Error p
Global Deletions
Number of CNVs per individual (31000) 2.94 1.40 0.036 1.82 1.37 0.18 1.33 1.71 0.44
Total CNV burden per individual (Mb) 0.088 0.053 0.098 0.048 0.020 0.015 0.038 0.023 0.10
Average CNV size per individual (Mb) 6.72 7.95 0.40 0.91 0.59 0.13 0.29 0.30 0.34
Global Duplications
Number of CNVs per individual (31000) 2.12 6.08 0.73 0.078 1.21 0.95 0.11 1.25 0.93
Total CNV burden per individual (Mb) 0.030 0.074 0.68 0.0016 0.0053 0.77 0.0011 0.0055 0.84
Average CNV size per individual (Mb) 0.24 1.03 0.82 0.022 0.10 0.83 0.0063 0.061 0.92
Genic Deletions
Number of CNVs per individual (31000) 2.82 1.70 0.097 4.37 2.04 0.033 4.19 2.71 0.12
Total CNV burden per individual (Mb) 0.052 0.062 0.40 0.064 0.022 0.0033 0.051 0.025 0.045
Average CNV size per individual (Mb) 0.42 6.17 0.95 0.94 0.46 0.042 0.38 0.23 0.089
Genic Duplications
Number of CNVs per individual (31000) 2.43 6.39 0.70 0.11 1.75 0.95 0.53 1.84 0.77
Total CNV burden per individual (Mb) 0.037 0.075 0.62 0.0017 0.0055 0.75 0.0013 0.0056 0.82
Average CNV size per individual (Mb) 0.25 0.89 0.78 0.032 0.082 0.69 0.0038 0.055 0.95
p values showing nominally significant associations are in bold. The beta value indicates the magnitude of the increase in the height Z score given the number of
CNVs per individual (in thousands) or the length of CNVs in Mb based on the linear regression.with schizophrenia.8 The global burdens of duplications
and common deletions were not associated with short
stature in our clinical cohort. Interestingly, an increased
CNV burden was found in short cases but not in tall cases
in our clinical cohort, suggesting that lower-frequency
deletions are more likely to impair growth than to cause
overgrowth. We extended these findings by performing
a quantitative-trait association analysis in a population-
based cohort and observed a correlation between lower-
frequency genic deletions and decreasing height. This
finding strongly supports our hypothesis that an
increasing burden of lower-frequency deletions can impair
growth and suggests that this phenomenon extends to the
general population.
In addition to analyzing the increase in global copy-
number burden, we performed an exploratory analysis of
regional association of CNVs with stature in our clinical
cohort. Overall, we observed far more significant p values
than we had expected to find, indicating that there might
be many regions with copy-number variants that affect
stature. However, we cannot exclude population stratifica-
tion as a contributing factor leading to this inflation of
test statistics. We identified three candidate regions
associated with stature in our clinical cohort; none of these
have known associations with stature or contain obvious
candidate genes. These preliminary regional associations
all require confirmation in additional cohorts. It is inter-
esting to note that two of these regions have multiple756 The American Journal of Human Genetics 89, 751–759, Decembolfactory receptor genes present. Although these are highly
polymorphic regions from the standpoint of copy-number
variation, our data set contains other highly CNV-
polymorphic regions that did not show any association
with height (data not shown). Of note, 11q11 copy-
number variation was recently found to be significantly
associated with early-onset obesity at a genome-wide
level.4 In that study, deletion of this region was associated
with an increased risk of obesity; our study showed
duplication of the region to be associated with decreased
stature. These results could be complementary because
obesity is often associated with increased linear growth
in childhood.
One prior study explicitly examined the role of CNVs in
height in a population cohort of 618 elderly Chinese Han
subjects,21 but did not examine global copy-number
burden. The researchers identified four possible regional
associations, although none of them reached a genome-
wide significance level. None of their four regions reached
experiment-wide significance in our study, although two
of the regions from their study (on 16p12.1 and 9p23)
did reach nominal significance (p < 0.05) in the duplica-
tion analysis in our cohort. Additionally, Kang et al. had
previously performed a genome-wide association analysis
of anthropometric traits in ~2,000 individuals of African
ancestry; in that analysis, they looked at the association
between common CNVs and height.22 They did not find
any CNV that reached genome-wide significance for aner 9, 2011
Figure 2. Quantile-Quantile Plot of p Values for Regional-CNV Association Analysis
Quantile-quantile plots for deletion and duplication CNVs are plotted separately. The x axis represents the negative log p value for the
expected distribution of p values, and the y axis represents the negative log p value for the observed p values. The circles forming a hori-
zontal line at anegative logpvalueof ~5on the y axis represent regionswhere thereareno simulationswith summedZscoresmore extreme
than our observed data. These areas represent regions with CNVs whose associations with stature have experiment-wide significance.association with height, and they did not perform a global
burden analysis for height.
There are a number of important limitations to our
study. First, our initial cohort is a clinically ascertained
cohort consisting of subjects who had undergone CGH
analysis for clinical reasons. Typical reasons for performing
this analysis in our institution include developmental
delay, autism spectrum disorders, and multiple congenital
anomalies. Therefore, it is possible that individuals with
an increased burden of rare CNVs are more likely to have
increased severity of an underlying disease, leading to
poor growth. However, our population-based analysis
suggests that this finding might be generalizable to a
more representative population. Further replication stud-
ies examining the role of copy-number variation in growthThe Americanwill be needed as additional cohorts with CNV data
become available.
A second limitation of our study is that we do not have
access to information about the genetic ancestry of the
subjects in the clinical cohort. It is possible that some of
the associations seen in our sample might be due to popu-
lation stratification, although ancestry was controlled for
in analyses of the population-based CARe cohort. Further-
more, our population-based study was performed exclu-
sively in African-American individuals and thus might
not be generalizable to other ancestries.
The third and final limitation is that the platform used
for determining the CNVs in the clinical cohort does not
allow for fine resolution of CNV length; it is possible that
multiple small copy-number polymorphisms were mergedJournal of Human Genetics 89, 751–759, December 9, 2011 757
into a larger CNV. Given this limitation, our association
analysis of individual regions was based on genomic loca-
tion rather than on individual CNVs. It is possible, and
perhaps even likely given the apparent size of the CNVs
in these regions, that our candidate regions actually repre-
sented an overall local burden of multiple small common
copy-number polymorphisms as opposed to an association
with individual larger and common CNVs present in those
regions. Given these concerns, we are not able to defini-
tively highlight particular causal CNVs but rather can
suggest regions of the genome in which copy-number vari-
ation, perhaps integrated over a local region, might affect
height.
In conclusion, we have performed a genome-wide asso-
ciation study of copy-number burden and height in a
clinical cohort. We found a significant increase in the
global burden of lower-frequency deletions and genic dele-
tions in a clinically ascertained population, demonstrating
that individuals who meet clinical indications for CNV
analysis and have short stature are more likely to have a
lower-frequency deletion. This finding suggests that the
presence of short stature might appropriately lower the
clinical threshold for obtaining a microarray-based anal-
ysis of copy-number variation. We extended these findings
into a population-based cohort of African-Americans and
observed a similar outcome. Our results suggest that
lower-frequency copy-number variants play a role in the
genetic basis of height. Thus, height, as a model polygenic
trait, is influenced by many rare sequence variants with
large effect size and hundreds of common SNPs with small
effect sizes, as well as low-frequency copy-number changes
and, in particular, genic deletions. Additional studies of
height and other polygenic traits will be needed if we are
to further assess the contribution of copy-number varia-
tion to human phenotypic variation.Supplemental Data
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